| Literature DB >> 27604489 |
Rohit Mehra1,2,3, Pankaj Vats1,3,4, Marcin Cieslik3, Xuhong Cao3,5, Fengyun Su3, Sudhanshu Shukla3, Aaron M Udager1, Rui Wang3, Jincheng Pan6, Katayoon Kasaian3, Robert Lonigro3, Javed Siddiqui3, Kumpati Premkumar4, Ganesh Palapattu7, Alon Weizer2,7, Khaled S Hafez7, J Stuart Wolf7, Ankur R Sangoi8, Kiril Trpkov9, Adeboye O Osunkoya10, Ming Zhou11, Giovanna Giannico12, Jesse K McKenney13, Saravana M Dhanasekaran1,3, Arul M Chinnaiyan14,2,3,5,7.
Abstract
Mucinous tubular and spindle cell carcinoma (MTSCC) is a relatively rare subtype of renal cell carcinoma (RCC) with distinctive morphologic and cytogenetic features. Here, we carry out whole-exome and transcriptome sequencing of a multi-institutional cohort of MTSCC (n = 22). We demonstrate the presence of either biallelic loss of Hippo pathway tumor suppressor genes (TSG) and/or evidence of alteration of Hippo pathway genes in 85% of samples. PTPN14 (31%) and NF2 (22%) were the most commonly implicated Hippo pathway genes, whereas other genes such as SAV1 and HIPK2 were also involved in a mutually exclusive fashion. Mutations in the context of recurrent chromosomal losses amounted to biallelic alterations in these TSGs. As a readout of Hippo pathway inactivation, a majority of cases (90%) exhibited increased nuclear YAP1 protein expression. Taken together, nearly all cases of MTSCC exhibit some evidence of Hippo pathway dysregulation. SIGNIFICANCE: MTSCC is a rare and relatively recently described subtype of RCC. Next-generation sequencing of a multi-institutional MTSCC cohort revealed recurrent chromosomal losses and somatic mutations in the Hippo signaling pathway genes leading to potential YAP1 activation. In virtually all cases of MTSCC, there was evidence of Hippo pathway dysregulation, suggesting a common mechanistic basis for this disease. Cancer Discov; 6(11); 1258-66. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 1197. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27604489 PMCID: PMC5096979 DOI: 10.1158/2159-8290.CD-16-0267
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397